Intrexon Corporation (Public - NYSE: XON) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.
Shrimp Season in Jeopardy as Tensions Persist Argentina
Despite the efforts of the Government of Chubut to bring the parties in conflict closer together and promote dialogue, the season continues to struggle. The STIA and SUPA delay the negotiations and an...
Ocean Network Express Unveils Asia Pacific 1 (AP1) Worldwide
Ocean Network Express (ONE) announces the launch of the Asia Pacific 1 (AP1) service, a new route connecting Asia and the U.S. West Coast.
Due to sustained growth of USA import volumes from Asia to...
Copyright 1995 - 2024 Seafood Media Group Ltd.| All Rights Reserved. DISCLAIMER